Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Yiping Mou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-9905-5233; OpenAlex author ID A5114031341. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 1, last author 3)
Trials
2
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2012: 1 paper · 2013: 1 trial · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 3 papers · 2020: 4 papers · 2021: none · 2022: 2 papers · 2023: 6 papers · 2024: 1 paper, 1 trial · 2025: 3 papers · 2026: 2 papers

Papers 26

  1. 18F-FDG PET Radiomic Analysis to Predict Occult Liver Metastases of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2025.10.024↗
  2. Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2025.510↗
  3. Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer. Co-author DOI 10.1186/s40364-024-00721-7↗
  4. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. Co-author DOI 10.4251/wjgo.v17.i7.103337↗
  5. Tetrahydromagnolol induces autophagic cell death by targeting the m6A reader protein YTHDF2 and enhances the efficacy of anti-PD-1 immunotherapy in pancreatic … Co-author DOI 10.7150/thno.112612↗
  6. Screening, optimization, and ADMET evaluation of HCJ007 for pancreatic cancer treatment through active learning and dynamics simulation. Last author DOI 10.3389/fchem.2024.1482758↗
  7. Correction: Functions and clinical applications of exosomes in Pancreatic cancer. Co-author DOI 10.1007/s11033-023-08906-3↗
  8. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular. Co-author DOI 10.1016/j.canlet.2023.216391↗
  9. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance. Last author DOI 10.1016/j.hbpd.2022.12.002↗
  10. Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study. First author DOI 10.1186/s12885-023-11493-y↗
  11. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-023-03080-z↗
  12. Protocadherin-1 serves as a prognostic biomarker and promotes pancreatic cancer progression by suppressing CD8+ T cell infiltration through CCL5-CCR5 axis. Co-author PMID 38058826↗
  13. Functions and clinical applications of exosomes in pancreatic cancer. Co-author DOI 10.1007/s11033-022-07765-8↗
  14. Clinical outcome comparison of laparoscopic radical antegrade modular pancreatosplenectomy vs. laparoscopic distal pancreatosplenectomy for left-sided pancreat… Co-author DOI 10.3389/fsurg.2022.981591↗
  15. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Co-author DOI 10.1007/s00464-019-06968-8↗
  16. Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. Co-author DOI 10.1615/critrevimmunol.2020033631↗
  17. Laparoscopic pancreaticoduodenectomy for pancreatic cancer: a hope or hype? Last author DOI 10.21037/hbsn-20-356↗
  18. Total laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis with meta-analysis Co-author DOI 10.21203/rs.3.rs-20225/v1↗
  19. Immunotherapy in pancreatic cancer: New hope or mission impossible? Co-author DOI 10.1016/j.canlet.2018.10.045↗
  20. Targeted Codelivery of Docetaxel and Atg7 siRNA for Autophagy Inhibition and Pancreatic Cancer Treatment. Co-author DOI 10.1021/acsabm.8b00764↗
  21. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s40880-019-0410-8↗
  22. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  23. LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution. Co-author DOI 10.1186/s12876-015-0411-2↗
  24. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  25. Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. Co-author DOI 10.1371/journal.pone.0087409↗
  26. [Construction of miRNA expression vector dual-targeting on HIF-1α/survivin genes and its effects on proliferation of pancreatic cancer Panc-1 cell line]. Co-author DOI 10.3785/j.issn.1008-9292.2012.01.014↗

Trials 2

  1. Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer Study chair NCT06722911↗
  2. Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Study director NCT01819961↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weiwei Jin · 13 shared papers, 2015–2026 · strength 2.18
  2. Zhichen Jiang · 5 shared papers, 2022–2026 · strength 1.11
  3. Hui‐Ju Wang · 4 shared papers, 2022–2023 · strength 0.80
  4. Yucheng Zhou · 4 shared papers, 2019–2023 · strength 0.52
  5. Yunyun Xu · 3 shared papers, 2014–2024 · strength 0.50
  6. Tao Xia · 2 shared papers, 2023–2026 · strength 0.49
  7. Nan Niu · 3 shared papers, 2020–2025 · strength 0.47
  8. Xinbing Sui · 2 shared papers, 2023–2025 · strength 0.40
  9. Li Li · 2 shared papers, 2023 · strength 0.39
  10. Xiu-jun Cai · 1 shared paper, 2025 · strength 0.37
  11. Maher Hendi · 1 shared paper, 2025 · strength 0.37
  12. Mingyang Liu · 2 shared papers, 2023 · strength 0.36
  13. Peng Xu · 2 shared papers, 2022–2023 · strength 0.32
  14. Shanying Gui · 1 shared paper, 2026 · strength 0.32
  15. Wenhui Ouyang · 1 shared paper, 2026 · strength 0.32
  16. Hezhi Fang · 1 shared paper, 2026 · strength 0.32
  17. J J Chen · 1 shared paper, 2026 · strength 0.30
  18. Yuanyu Wang · 2 shared papers, 2020–2023 · strength 0.28
  19. Miaozun Zhang · 3 shared papers, 2015–2020 · strength 0.26
  20. Mengni He · 1 shared paper, 2025 · strength 0.21
  21. Brian T. Herbst · 1 shared paper, 2025 · strength 0.21
  22. Sami Shoucair · 1 shared paper, 2025 · strength 0.21
  23. Keyu Li · 1 shared paper, 2025 · strength 0.21
  24. Jun-Ke Wang · 1 shared paper, 2025 · strength 0.21
  25. Lei Zheng · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.